TIDMAVCT

Avacta Group PLC

08 January 2018

8 January 2018

Avacta Group plc

("Avacta", "the Group" or "the Company")

Capital Markets Day Notification

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, today announces that it will host a Capital Markets Day for financial analysts and institutional investors on Wednesday, 7 February 2018 from 2pm to 4pm at finnCap's offices, 60 New Broad St, London, EC2M 1JJ.

The event will begin with a non-technical corporate update by Alastair Smith, Chief Executive Officer on strategy, key technical milestones and value inflection points and emerging themes within the business.

Following this update there will also be an opportunity to speak with other members of the Senior Management Team, whilst refreshments are served.

No new material information will be disclosed during the event.

If you would like to attend, please contact investorevents@avacta.com.

The presentation materials will be made available on the Group's website www.avacta.com

   -      Ends -

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                        Tel: +44 (0) 
  Alastair Smith, Chief Executive         844 414 0452 
  Officer                                 www.avacta.com 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd                             Tel: +44 (0) 
  Geoff Nash / Giles Rolls - Nominated    207 220 0500 
  Adviser                                 www.finncap.com 
  Tim Redfern / Alice Lane / Nikita 
  Jain - Corporate Broking 
                                          Tel: +44 (0) 
  WG Partners                             203 705 9318 
  Nigel Birks / Nigel Barnes              Tel: +44 (0) 
  David Wilson / Claes Spang              203 705 9217 
                                          www.wgpartners.co.uk 
 Zyme Communications (Trade and          Tel: +44 (0)7787 
  Regional Media)                         502 947 
  Katie Odgaard                           katie.odgaard@zymecommunications.com 
 
 
  Yellow Jersey PR (Financial Media       Tel: +44 (0)7764 
  and IR)                                 947137 
  Sarah Hollins                           avacta@yellowjerseypr.com

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUGUMUGUPRGMP

(END) Dow Jones Newswires

January 08, 2018 02:00 ET (07:00 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Avacta Charts.